Arrowhead Pharmaceuticals, Inc.
ARWR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | 4.75 | -2.39 |
| FCF Yield | -7.15% | 26.77% | -6.55% | -6.83% |
| EV / EBITDA | -18.72 | 5.67 | -19.01 | -18.10 |
| Quality | ||||
| ROIC | -13.65% | 26.63% | -17.40% | -15.60% |
| Gross Margin | 77.59% | 100.00% | 100.00% | 42.47% |
| Cash Conversion Ratio | 0.87 | 1.25 | 0.83 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 32.54% | 27.75% | -54.57% | -51.86% |
| Free Cash Flow Growth | -134.54% | 395.70% | 4.78% | -24.36% |
| Safety | ||||
| Net Debt / EBITDA | -3.93 | 1.40 | -3.18 | -2.66 |
| Interest Coverage | -6.79 | 17.62 | -7.46 | -11.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -446.55 | 0.39 | 90.00 | -75.53 |